Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings.
Vol 23, No 16S (June 1 Supplement), 2005: 2
© 2005 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Giantonio, B. J. Articles by Benson, A. B. Search for Related Content PubMed Articles by Giantonio, B. J. Articles by Benson, A. B.

Abstract

High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200

Univ of Pennsylvania, Philadelphia, PA; Dana-Farber Cancer Inst, Boston, MA; Fox Chase Cancer Ctr, Philadelphia, PA; Thomas Jefferson Univ, Philadelphia, PA; Mayo Clinic, Rochester, MN; Mount Sinai Medcl Ctr, Miami, FL; Northwestern Univ, Chicago, IL

2

Background: The humanized monoclonal antibody bevacizumab (BEV) binds VEGF, inhibits angiogenesis, and improves survival when combined with chemotherapy for advanced colorectal cancer. Methods: E3200 is a randomized phase 3 trial of high-dose BEV (10 mg/kg, IV, biweekly) either alone, or in combination with FOLFOX4 (biweekly administration of: oxaliplatin 85 mg/m², day 1; leucovorin 200 mg/m² IV 2hrs and fluorouracil 400 mg/m² IV bolus followed by fluorouracil 600 mg/m² CIV for 22hrs, days 1 & 2), compared to FOLFOX4 alone, in patients with previously treated advanced colorectal cancer. Eligible patients had an ECOG PS of 0–2 and must have been treated with a fluoropyrimidine and an irinotecan-based regimen used either alone or in combination. Prior BEV use was not allowed. The endpoints of E3200 include survival (OS), progression free survival (PFS) and response rate (RR). Results: 829 patients were accrued from November 2001 to April 2003. The bevacizumab alone arm of the study was closed in March 2003. Median follow-up is 18.7 months. Efficacy results and limited toxicity findings of E3200 will be presented. Bowel perforation was infrequent (1.1%) but occurred only in patients on E3200 treated with BEV. Conclusion: BEV administered at 10 mg/kg in combination with FOLFOX4 is well tolerated and improves OS and PFS in advanced colorectal cancer patients previously treated with irinotecan and a fluoropyrimidine.

View larger version (26K): [in this window] [in a new window]

Abstract presentation from the 2005 ASCO Annual Meeting